About mbx biosciences inc - MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
MBX At a Glance
MBX Biosciences, Inc.
11711 North Meridian Street
Carmel, Indiana 46032
| Phone | 1-317-659-0200 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -86,971,000.00 | |
| Sector | Health Technology | Employees | 63 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MBX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.838 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.957 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
MBX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,380,492.063 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MBX Liquidity
| Current Ratio | 24.623 |
| Quick Ratio | 24.623 |
| Cash Ratio | 24.118 |
MBX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -26.61 |
| Return on Equity | -27.757 |
| Return on Total Capital | -23.517 |
| Return on Invested Capital | -27.736 |
MBX Capital Structure
| Total Debt to Total Equity | 0.162 |
| Total Debt to Total Capital | 0.162 |
| Total Debt to Total Assets | 0.155 |
| Long-Term Debt to Equity | 0.115 |
| Long-Term Debt to Total Capital | 0.115 |